#semaglutide

A Penn-led analysis compared seven cardiometabolic outcomes across GLP-1 trial programs, while Mayo researchers identified a possible obesity phenotype associated with a different retrospective tirzepatide response. Together they sharpen the research questions, but they do not create a consumer test or treatment selector.

Neither the Wegovy nor the Zepbound prescribing information mentions alcohol. This is what the labels do say about hypoglycemia and nausea, what the craving research has and has not shown, and what changes if you also take insulin or a sulfonylurea.

Berberine picked up the nickname "nature's Ozempic" on TikTok. The two compounds act on different targets, and the meta-analysis that looked directly at body weight found no significant effect.

Every legal route to semaglutide runs through a licensed prescriber and a licensed pharmacy. This is the decision tree: how legitimate telehealth flows work, brand versus compounded, and the red flags that mark an illegal seller.

A weight plateau on semaglutide or tirzepatide has four separate causes, and they do not share an answer. Here is how to tell which one you are looking at, using what the STEP and SURMOUNT trials actually measured.

Clinical trials show 14.9-20.7% body weight loss with semaglutide depending on dose. Standard Wegovy (2.4mg): 14.9-17% over 68 weeks. Wegovy HD (7.2mg, FDA-approved March 2026): 20.7% over 72 weeks. Month-by-month breakdown from the STEP trials.

Updated July 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the SURMOUNT-5 head-to-head trial (NEJM 2024): a 47% greater relative reduction confirmed by 2026 systematic meta-analyses. Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Full cost and side-effect comparison.

As of August 2026, two FDA-approved oral GLP-1 weight-loss pills exist: Foundayo (orforglipron, 12.4% in ATTAIN-1, LillyDirect from $149/mo at 0.8 mg with a dose/refill ladder to $349, no fasting) and the Wegovy pill (semaglutide 25mg, 16.6% in OASIS, NovoCare from $149/mo, dose-dependent, 30-minute pre-dose fast). These were separate trials. Medicare covers both pills at a $50/mo Bridge copay for eligible patients.

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

Verified August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,027.51/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). NovoCare lists each pen at $199/mo for the first two low-dose fills; Wegovy then costs $349/mo at standard strengths ($399 HD), while Ozempic costs $349/mo at 0.25-1mg or $499/mo at 2mg. Pills start at $149/mo and are dose-dependent.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

FDA resolved the semaglutide shortage on February 21, 2025 and ended temporary shortage-based enforcement discretion on April 22 for 503A pharmacies and May 22 for 503B facilities. This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

Verified May 8, 2026, Updated August 12, 2026: On April 30, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use based on clinical need. The public comment period closed July 30, 2026 (Docket FDA-2018-N-3240; extension notice 91 FR 38719, published June 26, 2026). Days before that deadline, the Pharmacy Compounding Advisory Committee voted on seven peptides nominated for the separate 503A list and recommended six. Those votes are advisory, not FDA approval, and the 503B proposal was not final when last checked.

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified August 7, 2026: NovoCare lists the brand-name Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and the oral pill from $149/mo, dose-dependent; Zepbound starts at $299/mo via LillyDirect. Compounded offerings may advertise lower prices but require product- and prescription-specific regulatory review.

Verified July 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Verified August 2026: Oral Wegovy (25mg daily pill) produced 16.6% weight loss in OASIS vs 14.9% for injectable Wegovy (2.4mg weekly) in STEP-1. NovoCare lists the pill from $149/mo and pen from $199/mo, prescription required and dose-dependent. Full cross-trial comparison.

Verified July 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified July 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

A source-bounded guide to FDA warning letters involving compounded GLP-1 marketing, labeling, and manufacturing. Our linked tracker is finite and does not certify safety or compliance.

GLP-1 patches sold online don't contain semaglutide or tirzepatide, they're herbal supplements. Here's what the science says and what actually works.